Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

195.93 +0.68 (+0.35%)
Official Closing Price Updated: 7:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
Via Investor Brand Network
News headline image
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More
EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers. ↗
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
News headline image
Johnson & Johnson's Options: A Look at What the Big Money is Thinking ↗
 
Via Benzinga
News headline image
In-Depth Analysis: Johnson &amp; Johnson Versus Competitors In Pharmaceuticals Industry ↗
 
Via Benzinga
News headline image
Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug ↗
Johnson & Johnson reveals Erleada's 23% lower risk of death over Xtandi in a real-world study of prostate cancer patients, while also announcing a $2 billion biologics facility to support its expanding... 
Via Benzinga
News headline image
Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients ↗
Johnson & Johnson and Legend Biotech presented new data from the Phase 3 CARTITUDE-4 study, showing Carvykti significantly extends survival in multiple myeloma patients, reducing the risk of death by... 
Via Benzinga
News headline image
15 Best Dividend Stocks for Lifelong Passive Income ↗
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
News headline image
2 Excellent Dividend Stocks to Buy With Less Than $200 ↗
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years. 
Via The Motley Fool
News headline image
Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma ↗
Legend Biotech said its J&J-partnered CAR-T drug cut the risk of death by 45% over standard treatment for multiple myeloma. 
Via Investor's Business Daily
News headline image
Why NYSE:JNJ provides a good dividend, while having solid fundamentals. ↗
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
News headline image
The Latest Analyst Ratings For Johnson & Johnson ↗
 
Via Benzinga
News headline image
Unpacking the Latest Options Trading Trends in Johnson & Johnson ↗
 
Via Benzinga
News headline image
Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment ↗
Johnson & Johnson's recent studies reveal impressive response rates for Talvey in combination with Tecvayli and other therapies, demonstrating significant potential in treating relapsed or refractory... 
Via Benzinga
News headline image
For those who appreciate value investing, NYSE:JNJ is a compelling option with its solid fundamentals. ↗
JOHNSON & JOHNSON (NYSE:JNJ) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
Why Masimo Stock Crushed the Market Today ↗
The company seems to be effecting a smooth transition in its leadership. 
Via The Motley Fool
News headline image
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗
Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks... 
Via Benzinga
News headline image
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off ↗
These dividend players could lift your portfolio no matter what the market is doing. 
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Is Johnson & Johnson Stock a Buy? ↗
This healthcare blue chip is making all the right moves to reward shareholders. 
Via The Motley Fool
News headline image
Attorneys Vow to Oppose J&J’s Third Bankruptcy Attempt
From Beasley Allen Law Firm
Via Business Wire
News headline image
Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims
From Johnson & Johnson
Via Business Wire
News headline image
Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients ↗
Johnson & Johnson's Rybrevant (amivantamab) received FDA approval for use with standard chemotherapy in advanced non-small cell lung cancer with specific EGFR mutations. 
Via Benzinga
News headline image
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease ↗
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
News headline image
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure? ↗
Pharma stock have been on the rise in the latter half of the year, but the 2024 election remains a wild card for shares. 
Via Investor's Business Daily
News headline image
2 Vanguard Index Funds Could Turn $400 Per Month Into $16,800 in Annual Dividend Income by Retirement ↗
This two-step strategy could set investors up with a large sum of passive income in retirement. 
Via The Motley Fool
News headline image
Chinese Biotech BeiGene Labeled 'Unique Investment' As Analyst Confident In Lead Cancer Drug ↗
JMP Securities has initiated coverage on BeiGene highlighting the Chinese biotech company as a 'unique investment opportunity.' The firm's leading drug, Brukinsa (zanubrutinib), is emerging in the... 
Via Benzinga
News headline image
Top 3 Dividend Stocks to Beat Market Volatility and Boost Returns
These reliable dividend stocks are great buys, with shares still near the bottom of long-term ranges and accelerating growth expected in 2025. 
Via MarketBeat
Topics Economy
News headline image
Time To Invest And Or Trade In Bio-Tech Stocks? ↗
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
News headline image
Should You Buy Novavax Stock After This Regulatory Win? ↗
The biotech continues to earn important wins, but is it enough? 
Via The Motley Fool
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.